LENZ Therapeutics Inc (LENZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $129.77M
Last updated: Nov 17, 2026 at 11:05 AM ET
LENZ Therapeutics Inc (LENZ) Stock Forecast
Analysts expect LENZ Therapeutics (LENZ) to earn -$4.12 per share in the fiscal year ending Dec 31, 2026, on revenue of $14.47M. Of 6 analysts, 4 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.33, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 66.7% |
| Hold | 2 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 125.5%.
- Fiscal year ending Dec 31, 2026
- -$4.12
- EPS consensus, revenue $14.47M
- Fiscal year ending Dec 31, 2027
- -$1.35
- EPS consensus, revenue $32.63M
- Next report
- Mar 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.12 | -$4.37 to -$3.81 | 6 | $14.47M | $14.10M to $15.00M | 6 |
| Dec 31, 2027 | -$1.35 | -$2.35 to -$0.61 | 7 | $32.63M | $21.30M to $49.64M | 7 |
Quarterly Estimates
The EPS consensus rises from -$0.91 for the quarter ending Dec 31, 2026 to -$0.47 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.91 | -$1.22 to -$0.67 | 9 | $4.29M | $3.23M to $7.08M | 9 |
| Mar 31, 2027 | -$0.47 | -$0.59 to -$0.39 | 3 | $5.17M | $4.00M to $6.50M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 1 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$4.56.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.12 | -$4.20 | -$4.25 | -$4.25 | -$4.56 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.35 | -$2.64 | -$3.08 | -$3.08 | -$3.51 | N/A |
| Quarter ending Mar 31, 2027 | -$0.47 | -$0.62 | -$1.05 | -$1.05 | -$1.25 | N/A |
Frequently Asked Questions About LENZ
What is the LENZ stock forecast?
Consensus analyst estimates put LENZ Therapeutics's EPS at -$4.12 for the fiscal year ending Dec 31, 2026, on revenue of $14.47M. The consensus rating from 6 analysts is Buy.
How do analysts rate LENZ stock?
Of 6 analysts covering LENZ Therapeutics, 0 rate it Strong Buy, 4 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from LENZ next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.12, with estimates from -$4.37 to -$3.81 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.35, with estimates from -$2.35 to -$0.61 from 7 analysts.
What revenue do analysts expect from LENZ Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $14.47M, with estimates from $14.10M to $15.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $32.63M, with estimates from $21.30M to $49.64M.
How many analysts cover LENZ?
6 analysts rate LENZ Therapeutics stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
LENZ pages: Overview, Earnings, Forecast, Financials, Competitors